Get Newsletter
Alzheimer Research Forum - Networking for a Cure Alzheimer Research Forum - Networking for a CureAlzheimer Research Forum - Networking for a Cure
  
What's New HomeContact UsHow to CiteGet NewsletterBecome a MemberLogin          
Papers of the Week
Current Papers
ARF Recommends
Milestone Papers
Search All Papers
Search Comments
News
Research News
Drug News
Conference News
Research
AD Hypotheses
  AlzSWAN
  Current Hypotheses
  Hypothesis Factory
Forums
  Live Discussions
  Virtual Conferences
  Interviews
Enabling Technologies
  Workshops
  Research Tools
Compendia
  AlzGene
  AlzRisk
  Antibodies
  Biomarkers
  Mutations
  Protocols
  Research Models
  Video Gallery
Resources
  Bulletin Boards
  Conference Calendar
  Grants
  Jobs
Early-Onset Familial AD
Overview
Diagnosis/Genetics
Research
News
Profiles
Clinics
Drug Development
Companies
Tutorial
Drugs in Clinical Trials
Disease Management
About Alzheimer's
  FAQs
Diagnosis
  Clinical Guidelines
  Tests
  Brain Banks
Treatment
  Drugs and Therapies
Caregiving
  Patient Care
  Support Directory
  AD Experiences
Community
Member Directory
Researcher Profiles
Institutes and Labs
About the Site
Mission
ARF Team
ARF Awards
Advisory Board
Sponsors
Partnerships
Fan Mail
Support Us
Return to Top
Home: Disease Management: Treatment
Ginkgo Biloba


back to Drugs and Therapies


Important Notice: The Forum does not endorse any medical product or therapy. ALL medications and supplements should be taken ONLY under the supervision of a physician, due to the possibility of side-effects, drug interactions, etc.

Ginkgo Biloba EGb 761

Primary medical role: Improve cognitive capacities.

Role in Alzheimer's disease: Improve cognition in mild/moderate AD patients.

Approved by FDA for Alzheimer's use?: No.

Pharmacological role: Possibly, via antioxidant, or antiplatelet actions.

Contraindications: None known.

Side effects: Slightly higher rates of GI irritation, allergic skin reaction, and headache, in comparison to placebo groups.

Evidence pro its efficacy: A recent American, multi-center, placebo-controlled, double-blind, randomized trial demonstrated modest improvements in patients treated with Ginkgo biloba extract relative to patients given placebo only.

Evidence con its efficacy: The improvements ascribed to Ginkgo extract were fairly modest.

Dosage 40 mg, thrice daily with meals.

Cost:

Selected References:

Wettstein A. Cholinesterase inhibitors and Gingko extracts--are they comparable in the treatment of dementia? Comparison of published placebo-controlled efficacy studies of at least six months' duration. Phytomedicine. 2000 Jan;6(6):393-401. Abstract.

Simanyi M. Use of special Ginkgo biloba extract for cognitive disorders in the elderly. Wien Med Wochenschr. 1999;149(8-10):231-4. Review. Article in German. Abstract.

Clostre F. Ginkgo biloba extract (EGb 761). State of knowledge in the dawn of the year 2000. Ann Pharm Fr. 1999 Jul;57 Suppl 1:1S8-88. Article in French. Abstract.

Perry EK, Pickering AT, Wang WW, Houghton PJ, Perry NS. Medicinal plants and Alzheimer's disease: from ethnobotany to phytotherapy. J Pharm Pharmacol. 1999 May;51(5):527-34. Abstract.

Itil TM, Eralp E, Ahmed I, Kunitz A, Itil KZ. The pharmacological effects of ginkgo biloba, a plant extract, on the brain of dementia patients in comparison with tacrine. Psychopharmacol Bull. 1998;34(3):391-7. Abstract.

Maurer K. Ihl R. Dierks T. Frolich L. Clinical efficacy of ginkgo biloba special extract EGb 761 in dementia of the Alzheimer type. Journal of Psychiatric Research. 31(6):645-655, 1997 Nov-Dec. Abstract.

Le Bars PL, Katz MM, Berman N, Itil TM, Freedman AM, Schatzberg AF. A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia. North American EGb Study Group. JAMA. 1997 Oct 22-29;278(16):1327-32. Abstract.

Kanowski S. Herrmann WM. Stephan K. Wierich W. Horr R. Proof of efficacy of the ginkgo biloba special extract EGb 761 in outpatients suffering from mild to moderate primary degenerative dementia of the Alzheimer type or multi-infarct dementia. Pharmacopsychiatry. 1996 Mar;29(2):47-56. Abstract:

Stoll S, Scheuer K, Pohl O, Muller WE. Ginkgo biloba extract (EGb 761) independently improves changes in passive avoidance learning and brain membrane fluidity in the aging mouse. Pharmacopsychiatry 29 (4): 144-149 (Jul 1996). Abstract.

Loas G, Rose D, Nowaczkowski P, Lernout P, Duron B. [Translated from French] . Ann Med Psychol (Paris) 154 (3): 202-203 (Jun 1996). Abstract.

Mizuno M, Droy-Lefaix MT, Packer L. Ginkgo biloba extract EGb 761 is a suppresser of AP-1 transcription factor stimulated by phorbol 12-myristate 13-acetate. Biochem Mol Biol Int 39 (2): 395-401 (May 1996). Abstract.

Letzel H, Schoop W. Ginkgo biloba extract EGb 761 and pentoxifylline in intermittent claudication. Secondary analysis of the clinical effectiveness (see comments) [Translated from German] . Vasa 21 (4): 403-410 (1992). Abstract.

Halama P, Bartsch G, Meng G. Disorders of brain performance of vascular origin. Randomized double-blind study of the effectiveness of Ginkgo biloba extract [Translated from German]. Fortschr Med 106 (19): 408-412 (Jun 1988). No abstract available.

Taylor JE. Neuromediator binding to receptors in the rat brain. The effect of chronic administration of Ginkgo biloba extract [Translated from French]. Presse Med 15 (31): 1491-1493 (Sep 1986). Abstract.

Print this page
Email this page
Alzforum News
Papers of the Week
Text size
Share & Bookmark
Participate in Research
See a list of research studies, projects, and clinical trials in search of research participants.
Copyright © 1996-2013 Alzheimer Research Forum Terms of Use How to Cite Privacy Policy Disclaimer Disclosure Copyright
wma logoadadad